Lemonade stock

Lemonade's stock performance and financial metrics suggest a company facing challenges but with potential for growth and interest from investors.

1. **Stock Performance**:
- **Recent Closing Price**: As of August 13, 2024, Lemonade's stock (LMND) closed at $15.62, with a support level at $15.36 and a resistance level at $15.92.
- **Trend Analysis**: The stock has experienced a 3.24% increase over the past year, but a significant drop of 16.16% over the past three months.

|Ticker|Name|Date|Resistance Level (Narrow)|Closing Price|Support Level (Narrow)|code|market_code|
|---|---|---|---|---|---|---|---|
|LMND.N|Lemonade|20240813|15.9207|15.62|15.3561|LMND|169|

2. **Technical Indicators**:
- **Moving Averages**: The 5-day moving average is $15.36, the 10-day moving average is $16.09, and the 50-day moving average is $17.82. This indicates that the stock is currently below its short-term and medium-term moving averages, suggesting a bearish trend.
- **RSI**: The Relative Strength Index (RSI) is at 30.41, which is considered oversold and could indicate a potential reversal or bounce back.
- **MACD**: The Moving Average Convergence Divergence (MACD) is -1.36, and the KDJ indicator is at 10.9, suggesting bearish momentum.

|Ticker|Name|Date|bollinger lower band|RSI|KDJ|MACD|code|market_code|
|---|---|---|---|---|---|---|---|---|
|LMND.N|Lemonade|20240813|12.4690|30.4134|10.9037|-1.3576|LMND|169|

3. **Financial Ratios**:
- **P/E Ratio**: The Price-to-Earnings (P/E) ratio is -5.32, which is negative and could indicate that the company is not profitable as currently reported.
- **P/S Ratio**: The Price-to-Sales (P/S) ratio is 1.75, which is relatively high, suggesting that the market is valuing the company's sales at a premium.
- **P/B Ratio**: The Price-to-Book (P/B) ratio is 1.75, which is within the range of industry peers, indicating that the stock may be fairly valued based on its tangible assets.

|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|code|market_code|
|---|---|---|---|---|---|---|---|
|LMND.N|Lemonade|20240813|-5.323687||1.746625522890428|LMND|169|

4. **Fundamentals**:
- **Free Cash Flow**: The company reported a negative free cash flow of $98.3 million as of June 30, 2024.
- **Debt-to-Equity Ratio**: The debt-to-equity ratio is not provided, but a negative free cash flow could indicate financial strain if the company relies heavily on debt financing.

5. **Market Sentiment**:
- **Trading Volume**: The trading volume was 1.1 million shares, indicating moderate investor interest.
- **Average Price Target**: The average price target is not provided, but the consensus rating is "Moderate Buy" with a predicted upside.
- **Net Fund Flow**: The net fund flow was $347,356.31, indicating some positive investment inflows.

|Ticker|Name|Date|Average Price Target|Trading Volume|Consensus Rating|code|market_code|
|---|---|---|---|---|---|---|---|
|LMND.N|Lemonade|20240813||1098997||LMND|169|

6. **Market Position and Forecast**:
- **Market Capitalization**: Lemonade has a market cap of $1.11 billion.
- **ATR**: The Average True Range (ATR) is $1.3, indicating high volatility.
- **Beta**: The stock has a beta of 1.78, suggesting it is more volatile than the market.
- **Volatility**: The weekly volatility is 3.57%, which is relatively high.

|Ticker|Name|Date|Weekly Volatility|Beta|code|market_code|
|---|---|---|---|---|---|---|
|LMND.N|Lemonade|20240812||1.78|LMND|169|
|LMND.N|Lemonade|20240813|3.565043||LMND|169|

7. **Future Outlook**:
- **Short-term Outlook**: The recent price action and technical indicators suggest that Lemonade's stock may continue to face downward pressure in the short term.
- **Long-term Outlook**: The company's innovative approach to insurance and the "Moderate Buy" consensus rating from analysts indicate potential for growth and value creation over the long term.

In summary, Lemonade's stock presents a complex picture with both bearish short-term indicators and positive long-term prospects. Investors should consider these factors along with their own risk tolerance and investment horizon when evaluating LMND stock.